Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 48 Parkinson's papers of 10,049 | 0.49 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 15493
Sealed predictions
- CFI in dopamine neurons, braak-0.20 (p 0.613) → +0.31 (p 0.416)receipt 15501
Swarm cases
receipt 15501: CFI in dopamine neurons, braak
- power
- full sample +0.04 (p 0.861, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.840, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.728, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.20, sign flips 5; without severely affected donors +0.04 (p 0.861, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CFI in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts